Objectives: To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as a single-tablet regimen (STR) using the PCR signal of the plasma viral load (pVL) assay and determination of plasma drug concentration (C 24 ).
Introduction
The ART therapeutic arsenal has recently increased with the licensing of co-formulations as single-tablet regimens (STR) including two NRTI and (i) one NNRTI (efavirenz or rilpivirine) or (ii) one integrase inhibitor (boosted elvitegravir or dolutegravir). STR greatly simplifies ART with the objectives of improving quality of life and favouring long-term adherence.
The randomized, open-label, Phase 3b, non-inferiority trials STRATEGY-PI and STRATEGY-NNRTI assessed the non-inferiority of a switch from a PI-based regimen or from an NNRTI-based regimen, respectively, to the co-formulated elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate STR compared with continuation of the PI-or NNRTI-based regimen.
1,2 These trials included moderately pretreated patients (receiving their first-or second-line ART regimen) with no history of virological failure (VF) and with plasma viral load (pVL) ,50 copies/mL for at least 6 months. Both trials showed the non-inferiority of the switch option, with 93% of the participants in the switch group maintaining pVL ,50 copies/mL at week (W) 48. 1, 2 In these trials, VF occurred in ,1% of the patients during the first year following the switch, with no emergence of resistance.
However, limited data are available on the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in a clinical cohort of patients virologically suppressed with a longer and a more diverse therapeutic history. Furthermore, the efficacy of this strategy when considering the residual viraemia, defined by the detection of a PCR signal below the limit of quantification, has not been assessed in an open clinical cohort and its relationship with concomitant antiretroviral plasma concentrations remains undetermined.
Assessment of residual viraemia is important since it has been associated with increased intima-media thickness on the common carotid artery segment, 3 and with higher levels of the proinflammatory marker IL-6. 4 In addition, some differences can be observed between the different antiretroviral drug classes. Indeed, previous studies have shown that residual viraemia was less frequent with NNRTI than with PI treatment, 5, 6 whereas data available regarding the impact of integrase inhibitors on residual viraemia are limited.
The aim of this study was to assess, in virologically suppressed patients switching their ART to the co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate STR, the proportion of patients with undetectable viraemia, defined as no PCR signal. In addition we evaluated in this population the proportion of those with adequate drug plasma concentrations.
Patients and methods

Study population
This was a prospective, observational, single-centre cohort study enrolling all successfully ART-treated patients, i.e. those with a pVL ,50 copies/mL, switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate STR between April 2014 and December 2014.
Ethics
All the patients enrolled in this study gave their written informed consent to have their medical chart recorded in the electronic medical record system Nadis V R (www.dataids.org; Fedialis Medica, Marly Le Roi, France, CNIL number 1171457, 24 May 2006), designed for the healthcare medical follow-up of HIV-infected patients.
Virological analysis
Historical resistance genotypes or the therapeutic history were available for all patients. Genotypic resistance tests of reverse transcriptase (RT) and integrase regions were performed according to the complete sequencing procedures and primer sequences described at www.hivfrenchresistance. org. Sequences were submitted to genotypic interpretation according to the Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) resistance algorithm (www.hivfrenchresistance.org, October 2015, version 25).
Plasma specimens were collected during routine follow-up at W4, W12, W24, W36 and W48, with an acceptable interval of 1 month, except for the W4 sample.
Plasma HIV-1 RNA quantification was performed using COBAS
.0 (Roche Molecular Systems, Branchburg, NJ, USA) with a limit of quantification of 20 copies/mL. PCRneg was defined as an undetected PCR signal, corresponding to an absence of residual viraemia. We defined PCRpos when a PCR signal was detected below the limit of quantification of 20 copies/mL.
A blip was defined as a transient pVL .50 copies/mL and a VF as two consecutive pVLs .50 copies/mL.
Pharmacological analysis
Plasma drug concentrations sampled 24 h post-dose (C 24 ) were measured using ultra-performance LC combined with tandem MS (UPLC-MS/MS) (Waters Corporation, Milford, MA, USA). 7 Elvitegravir C 24 values were interpreted according to the effective cut-off of 45 ng/mL, which corresponds to the in vitro IC 95 adjusted by protein binding. 8 For tenofovir and emtricitabine the usual mean + SD C 24 values were 44 + 22 and 90 + 70 ng/mL, respectively. 9 
Renal function assessment
We assessed estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation values.
Statistical analysis
Non-parametric Mann-Whitney tests were used for statistical comparisons. Continuous variables were described as median (25th-75th percentile) and qualitative variables by frequency and percentage.
Results
Patients' characteristics
This observational cohort assessed 151 virologically suppressed patients who had switched to elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate STR during the study period, with characteristics depicted in Table 1 (group 1).
Median CD4 cell count at time of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate STR initiation was 600 cells/ mm 3 (IQR 477-790). Median time since first ART and median time with pVL ,50 copies/mL before STR initiation were 5 years (IQR 3-9) and 24 months (IQR 9-44), respectively. Before elvitegravirbased STR initiation, 62 (41%) of the patients were receiving an NNRTI-based regimen, 72 (48%) a ritonavir-boosted PI-based regimen, 13 (9%) a raltegravir-based regimen and 4 (2%) other ART combinations. The main reason for switching to elvitegravir-based STR was simplification, i.e. reducing pill burden, (n " 94, 62%) since they received a median of three pills before the switch to the elvitegravir-based STR, but patients also switched for treatmentrelated adverse events: neuropsychiatric side effects (n " 34, 23%) associated with the use of efavirenz in particular (n " 23, 15%).
Historical genotypes
One hundred and twenty of the 151 (79%) patients had one previous plasma genotypic resistance test available, including 89 pretherapeutic genotypes and 47 genotypes at the time of a previous VF. Mutations associated with resistance to NRTI were detected in six patients (5%). The mutations E44D, T69N, L74I, T215A, T215F and T215S were detected, not resulting in resistance to emtricitabine or tenofovir. A historical integrase sequence was available for 38 patients (25%) with no evidence of resistance mutations.
Immunovirological and pharmacological outcomes
In this observational study, plasma specimens were available for 61 patients at W4, 98 at W12, 79 at W24, 76 at W36 and 65 at W48.
The number of patients still receiving elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate and maintaining pVL ,50 copies/mL was 61 (100%), 96 (98%), 76 (96%), 71 (93%) and 63 (97%) at W4, W12, W24, W36 and W48, respectively ( Figure 1 A total of 237 drug plasma C 24 values were measured during the first year of STR. Overall, the median tenofovir, emtricitabine, elvitegravir and cobicistat C 24 values were 69 (IQR 54-84), 145 (IQR 91-235), 648 (IQR 348-989) and 49 ng/mL (IQR 16-108), respectively. During the first year of elvitegravir-based STR, 95%, 97% and 84% of tenofovir, emtricitabine and elvitegravir C 24 values were adequate or above the respective cut-offs, respectively ( Figure 2 ). Six patients (4%) had adherence difficulties confirmed by the absence of detectable drug in plasma samples. Three of the six patients discontinued the STR, and no impact on the pVL could be evidenced in the three remaining patients.
Inter-patient variabilities of tenofovir, emtricitabine, elvitegravir and cobicistat C 24 values were 42%, 83%, 195% and 69%, respectively. Intra-patient variabilities of tenofovir, emtricitabine, elvitegravir and cobicistat C 24 values were 32%, 46%, 82% and 53%, respectively.
During the follow-up, 26 patients (17%) discontinued STR due to adverse events occurring between W1 and month 10 after the initiation of the elvitegravir-based STR: 4 for gastro-intestinal side Switch to elvitegravir single-tablet regimen JAC effects, 4 for neuropsychiatric side effects, 1 for VF, 2 for renal toxicities, 1 for a musculoskeletal side effect, 4 for drug-drug interactions with direct antiviral agents against hepatitis C, 1 for a drug-drug interaction with direct factor Xa inhibitor, 3 for pregnancies and 6 for other reasons. Among the four patients presenting drug-drug interactions with direct antiviral agents against hepatitis C virus, two received ombitasvir/paritaprevir/ritonavir and ribavirin, one received ombitasvir/paritaprevir/ritonavir and dasabuvir, and one received sofosbuvir and daclatasvir, all for 12 weeks.
Among the four patients with neuropsychiatric side effects, occurring during the first 3 months following elvitegravir-based STR initiation in all cases but one, plasma drug C 24 values were available for two patients, with elvitegravir C 24 overexposure in one case (elvitegravir C 24 " 974 ng/mL). Among the four patients with gastrointestinal side effects, occurring during the first 3 months following STR initiation in all cases, plasma drug C 24 values were available for three with elvitegravir plasma drug C 24 values above the median value in two cases at the timepoint before STR discontinuation (elvitegravir C 24 " 850 and 690 ng/mL).
Description of patients with pVL .50 copies/mL
During the follow-up a pVL .50 copies/mL was observed in nine patients, with a median of 279 copies/mL (IQR 143-817). Among them, four were considered a viral blip and five a VF (Table 2) . Thus, the proportion of patients experiencing a VF was 3.3% (95% CI 0.4-6.2). Plasma drug C 24 values were available for two patients at the timepoint of the first pVL .50 copies/mL showing adequate elvitegravir C 24 , but low tenofovir and emtricitabine C 24 in one patient and suboptimal elvitegravir C 24 in the second patient. None of the patients experiencing a VF was switched from a raltegravirbased regimen; all were switched from a ritonavir-boosted PI-based regimen (darunavir, n " 4; atazanavir, n " 1). Three of the five patients experiencing a VF were receiving their first-line treatment before the switch to the elvitegravir-based STR. The two remaining patients had received three and nine previous ART regimens before initiating elvitegravir-based STR. 
Assessment of residual viraemia
Among patients with pVL ,20 copies/mL, the proportion of patients with no PCR signal (PCRneg) was 70%, 72%, 57%, 72%, 61% and 74% at baseline, W4, W12, W24, W36 and W48, respectively ( Figure 1) . Among the 30 patients with PCRneg at baseline and for whom pVL data with PCR signal information were available at W48, pVL remained PCRneg at W48 in 90% of them. Regarding all paired pVL and plasma drug C 24 data available at W24 (n " 49), the proportion of patients with adequate elvitegravir C 24 (.45 ng/mL) was 94% (n " 46). The three remaining patients with suboptimal elvitegravir C 24 (26, ,5 and ,5 ng/mL) had a PCRneg result.
No difference in median elvitegravir C 24 at W24 was observed between PCRneg pVL and pVL with a PCR signal (median 648 ng/mL, n " 31, and median 644 ng/mL, n " 13, respectively; P " 0.69).
Renal function follow-up
The median eGFR decreased slightly over the study period: it was 94 (IQR 84-109), 89 (IQR 76-102) and 82 mL/min/1.73 m 2 (IQR 70-95) at baseline, W24 and W48, respectively. None of the patients displayed an eGFR value ,50 mL/min/1.73 m 2 , whatever the timepoint. The mean decrease in eGFR between baseline and W24 was 9 mL/min/1.73 m 2 in the 60 patients with paired data at baseline and W24. At W48 the mean decrease in eGFR from baseline was 18 and 10 mL/min/1.73 m 2 in the patients switching from an NNRTI-based regimen and in the patients switching from a PI-based regimen, respectively. Regarding the two patients who discontinued elvitegravirbased STR for renal toxicity (at month 4 and month 9), both were receiving abacavir/lamivudine combined with atazanavir/ritonavir before the switch to the elvitegravir-based STR. At the time of discontinuation, they showed a decreased eGFR from baseline (from 58 to 37 mL/min/1.73 m 2 and from 83 to 66 mL/min/1.73 m 2 ) with an increased blood creatinine level, and one with available C 24 showed tenofovir plasma overexposure (tenofovir C 24 " 118 ng/mL).
Switch in patients with historical tenofovir and/or emtricitabine/lamivudine resistance mutations
During the same period of inclusion, 15 virologically suppressed patients (pVL ,50 copies/mL), exhibiting historical resistance mutations to tenofovir and/or to emtricitabine/lamivudine, were also switched to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. The genotypic susceptibility score (GSS) was 2 in 10 patients and 1.5 in 5 patients. Indeed, all viruses but one had the M184I/V mutation, and among the eight viruses harbouring both the M184V mutation and thymidine analogue mutations (TAMs), the presence of TAMs led to possible resistance to tenofovir in five cases according to the ANRS tenofovir resistance score.
These 15 patients had a longer therapeutic history than the 151 patients described above, with a median time since first ART of 16 years (IQR 13-18) and a median time with pVL ,50 copies/mL of 26 months (IQR 12-45) ( Table 1 , group 2). They had a median of five previous ART lines.
During the 1 year follow-up, two patients discontinued elvitegravir-based STR, one at W12 for intolerance and one switching at W36 for an NRTI-sparing regimen secondary to osteoporosis. One patient experienced VF at W12 with a pVL at 9717 copies/mL confirmed at 475 copies/mL; and two patients displayed a viral blip (73 copies/mL at W12 and 52 copies/mL at W48).
Regarding the only patient experiencing VF, historical genotypes showed the mutations L74I/V, M184V, T215F, K219Q, Switch to elvitegravir single-tablet regimen JAC leading to a GSS of 2, since tenofovir remained active, according to the ANRS tenofovir resistance score. Plasma drug concentrations were below the limit of quantification at the time of VF, suggesting poor adherence. Genotypic resistance tests performed at the two timepoints of VF showed RT mutations similar to those present in historical genotypes and no selection of resistance mutations in integrase.
The proportion of patients with pVL ,20 copies/mL was 83% (n " 5/6) at baseline, 92% (n " 11/12) at W24 and 89% (n " 8/9) at W48. Furthermore, among patients with pVL ,20 copies/mL having PCR signal information available, pVL was PCRneg in 4/4 patients at baseline, 6/8 patients at W24 and 4/5 patients at W48.
Discussion
This study assessed the efficacy, including the impact on residual viraemia, of a switch to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate STR in virologically suppressed patients (pVL ,50 copies/mL) from a clinical cohort with a follow-up of 1 year. Among these 151 patients, with no previous tenofovir or emtricitabine resistance, who received elvitegravir-based STR, 74% maintained virological suppression at W48 with no residual viraemia and 84% had adequate antiretroviral plasma concentrations of elvitegravir.
Our findings appear to be interesting since few data are available from clinical trials regarding the efficacy of switching to elvitegravir-based STR. One prospective open-label study among 48 patients showed that all maintained pVL ,50 copies/mL at W48, 10 confirming results from the STRATEGY-PI and STRATEGY-NNRTI trials, both of which showed that 93% of patients maintained virological suppression. 1, 2 Furthermore, in our clinical cohort 32% of the patients were from sub-Saharan Africa and 43% were infected with an HIV 'non-B' subtype. About half of the patients switched from a PI-based regimen and half from an NNRTI-based regimen. A high level of adherence (associated with adequate antiretroviral plasma exposures) was observed, resulting in a high level of maintenance of virological suppression, 97% of patients having pVL ,50 copies/mL at W48 with elvitegravir-based STR.
In our study, five VFs occurred during the 1 year follow-up and emergence of resistance was detected in two patients with available genotypic resistance data, both having selected RT and integrase resistance mutations. In contrast, in the STRATEGY-PI and STRAGEGY-NNRTI trials no emergence of resistance was observed; however, the criterion for performing a genotypic resistance test was a confirmed VF with pVL .400 copies/mL.
1,2
Interestingly, we also assessed virologically suppressed patients who initiated elvitegravir-based STR despite the presence of historical RT mutations leading to resistance to emtricitabine + tenofovir. Although it concerned a small number of patients (15), the 1 year follow-up showed a high level of sustainable virological suppression, with the occurrence of only one VF associated with inadequate drug plasma concentrations. These findings are of interest since clinical trials of drug regimen switching do not include this specific population of patients with previous VF.
To our knowledge, virological follow-up using the PCR signal in patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate has not been previously reported. In our study we showed that 70% of patients had no residual viraemia at baseline before switching to the STR and that this proportion remained stable during the follow-up: 72% at W24 and 74% at W48. These findings are similar to those we previously described in an observational cohort following a switch to tenofovir disoproxil fumarate/emtricitabine/rilpivirine STR. 11 In this latter study the proportion of patients with no residual viraemia remained stable around 70% during the first 2 years following rilpivirine-based STR initiation. 11 Thus, these switch options with recent STR, including different drug classes, such as NNRTIs or integrase inhibitors, do not impact on residual viraemia.
In the present study, no difference was found in median elvitegravir C 24 between patients with no PCR signal and those in whom a PCR signal was detected. Thus, there was no correlation between plasma drug C 24 and residual viraemia, as we previously observed in the observational cohort assessing switch to tenofovir disoproxil fumarate/emtricitabine/rilpivirine STR.
11
In this observational cohort, 26 (17%) patients discontinued elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate STR for adverse events, a higher proportion than those observed in the randomized trials STRATEGY-NNRTI and STRATEGY-PI, in which 7.6% and 8.5% of the patients stopped tenofovir disoproxil fumarate/emtricitabine/rilpivirine STR, respectively. 1, 2 In this study, median eGFR decreased slightly over the study period, from 94 (IQR 84-109) at baseline to 82 mL/min/1.73 m 2 (IQR 70-95) at W48, consistent with the established cobicistat effect on serum creatinine excretion inhibition and also with chronic tenofovir disoproxil fumarate use, which can worsen kidney function through dysfunction in the proximal tubular cells. 12, 13 In conclusion, our findings obtained in a clinical cohort confirmed data reported in randomized trials, with 97% of the patients maintaining pVL ,50 copies/mL at W48 and .90% having adequate drug plasma concentrations. In addition, these results were obtained in patients with a large proportion of HIV-1 non-B subtypes, and assessment of residual viraemia showed a stable proportion of patients (around 70%) with negative PCR during the first year following the switch to tenofovir disoproxil fumarate/ emtricitabine/elvitegravir/cobicistat STR.
